Table of Contents
- What Is Retatrutide and Why Does It Cause Side Effects?
- What Are the Commonly Reported Retatrutide Side Effects?
- What Are the Most Common Gastrointestinal Side Effects?
- What Are Abnormal Skin Sensations and How Often Do They Happen?
- Does Retatrutide Affect Heart Rate and Blood Pressure?
- Are There Serious Retatrutide Side Effects?
- How Many Patients Treated with Retatrutide Stopped?
- How Much Weight Did Participants Lose, and at What Cost?
- How Do Retatrutide Side Effects Compare to Other Weight Loss Drugs?
- What Is the FDA Approval Status of Retatrutide?
- Bottom Line
Key Takeaways
- Gastrointestinal symptoms lead the list, and they cluster around dose increases rather than running the whole time.
- Dysesthesia is the finding worth watching, appearing in 7% of Phase 2 participants and reaching 20.9% at 12 mg in Phase 3.
- Serious adverse effects matched placebo in Phase 2, with no medullary thyroid cancer or C-cell hyperplasia reported.
- Dropout rates swung widely between trials, from 5.1% to 18.2% at the same 12 mg dose.
- Retatrutide remains an investigational drug with no approved supply anywhere in the world.
Retatrutide is an injectable medication for weight loss and type 2 diabetes that Eli Lilly is still developing. It has not been approved by the United States Food and Drug Administration, so there is no official safety label listing its side effects.
What exists instead is trial data. Across Phase 2 and Phase 3 studies, researchers tracked thousands of participants at every dose level, and those results are public.
The short version: nausea leads the list. At the 12 mg dose, 43% of participants reported it in one Phase 3 trial, followed by diarrhea at 33%, vomiting at 21%, and an odd skin sensation called dysesthesia at nearly 21%.
Most were mild to moderate and eased within weeks. The catch is that these numbers shift a lot depending on the dose and the trial.
Below, we break down what each one reported.
What Is Retatrutide and Why Does It Cause Side Effects?
Retatrutide acts on three hormone pathways at once. It is a triple hormone receptor agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon.
That is why it produces more weight reduction than weight loss drugs working on one or two receptors. It is also why the side effect list looks the way it does.
Picture three switches flipping together instead of one. More switches, more knock-on metabolic effects.
The GLP-1 part slows how fast food leaves your stomach and helps reduce appetite. As a glucagon receptor agonist, it also raises energy expenditure, which matters later when we get to heart rate.
What Are the Commonly Reported Retatrutide Side Effects?
Gastrointestinal adverse events lead in every trial. The Phase 2 obesity trial in the New England Journal of Medicine found they occurred mainly during dose escalation, were predominantly mild to moderate, and eased with a 2 mg starting dose instead of 4 mg.
Across 48 weeks, adverse events of any kind were reported in 73 to 94% of participants on retatrutide against 70% on placebo. The highest rates showed up in the 8 mg and 12 mg groups.
Here is how the rates stack up at the 12 mg dose:
| Side effect | Phase 2, 12 mg | TRIUMPH-4, 12 mg | Diabetes trial, 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | Most frequently reported | 43% | 26.5% | 3 to 9% |
| Diarrhea | Common | 33% | 22.8% | About 4% |
| Vomiting | Common | 21% | 17.6% | About 2% |
| Constipation | Common | Reported | Reported | Low |
| Dysesthesia | 7% | 20.9% | 4.4% | 0 to 0.7% |
| Participants discontinued treatment | 6 to 16% | 18.2% | 5.1% | 0 to 4% |
Same drug, same dose, very different results. Phase 2 also recorded skin sensitivity events in 7% of participants against 1% on placebo, with none severe enough to stop treatment.
Which Trials the Side Effect Data Comes from
Those gaps make more sense once you know what each study covered. Nearly every number in this article traces back to one of four trials:
- Phase 2: 338 adults with obesity, 48 weeks, reported June 2023
- TRIUMPH-4: obesity plus knee osteoarthritis, 68 weeks, reported December 2025
- TRANSCEND-T2D-1: type 2 diabetes, 40 weeks, reported March 2026
- TRIUMPH-1: the pivotal obesity trial, 80 weeks, reported May 2026
Phase 2 tests whether a drug works and at what dose. Phase 3 trials like TRIUMPH-1 test it in far more people before a company applies for approval.
Trial length and patient group both shape the numbers. That is the main reason figures online disagree so much.
Why Side Effects Peak during Dose Escalation
Most symptoms appear in the first week or two after a dose increase, not steadily across treatment. They usually settle as your body adjusts.
Then they spike again at the next increase. That cycle repeats until you reach a maintenance dose, where things generally quiet down.
What Are the Most Common Gastrointestinal Side Effects?
Nausea, vomiting, diarrhea, and constipation share one cause, so they behave alike. Retatrutide slows how fast food moves through you, which can feel like nausea, bloating, or reflux depending on where things back up.
A safety review in the Journal of Pharmacy Technology found all four were more common than in the placebo group, and reported most often during dose escalation.
The same pattern showed up in the earliest study. In Phase 1, adverse events hit 63% of participants on retatrutide against 54% on placebo, with nausea and diarrhea leading and most cases mild to moderate.
That review reached a useful conclusion. Based on the completed studies, retatrutide's side effect profile looks very similar to GLP-1 receptor agonists and GLP-1/GIP dual agonists already on the market.
What Helped in the Trials
Researchers tested two starting points in Phase 2: 2 mg and 4 mg. People who began at 2 mg had less nausea and vomiting during the step-up period.
That one finding shaped the entire Phase 3 program. Beyond the slower start, the standard approaches used alongside these medications include:
- Eating smaller, more frequent meals to ease nausea
- Drinking more water to prevent dehydration from diarrhea
- Raising fiber intake gradually to help with constipation
- Skipping greasy or heavy meals, which tend to worsen vomiting
What Are Abnormal Skin Sensations and How Often Do They Happen?
Dysesthesia is an altered sense of touch. People describe burning, tingling, or skin that feels oddly sensitive to clothing or water.
It is not injury pain and not an allergic reaction. The skin looks normal, but ordinary contact feels off.
Phase 2 logged skin sensitivity events in 7% of people on retatrutide versus 1% on placebo. None were severe, and none led anyone to stop.
Phase 3 gave three different answers at the same 12 mg dose. TRIUMPH-4 reported 20.9%, TRIUMPH-1 reported 12.5%, and TRANSCEND-T2D-1 reported 4.4%. Placebo rates ran below 1% across all three.
The trials ran different lengths with different patient groups. Phase 2 ruled out one theory, finding these events were not tied to how much or how fast people lost weight. The glucagon component and its effect on peripheral nerves is the leading explanation.
Does Retatrutide Affect Heart Rate and Blood Pressure?
Yes on heart rate, and the pattern is gentler than it sounds. Phase 2 found a dose-dependent rise that peaked around week 24, then declined.
The rise at the top dose has been put at roughly 7 beats per minute. That is larger than tirzepatide or semaglutide produce.
Blood pressure moved the other way. Phase 2 showed improvements in both systolic and diastolic readings, along with better blood sugar control and lipid markers.
Are There Serious Retatrutide Side Effects?
The trial record reads quieter than the chatter around it. Phase 2 reported no cases of clinically meaningful low blood sugar.
Liver markers stayed steady too. Transient enzyme rises showed up in just 1% of participants, with average readings unchanged or lower by week 48.
What Trials Found about Thyroid Cancer
Phase 2 reported no medullary thyroid cancer and no C-cell hyperplasia. That answers a question a lot of people search for.
The thyroid warning on approved weight loss medications traces back to preclinical animal studies. It carries across the drug class as a label caution, has not been confirmed in humans, and has not appeared in retatrutide clinical trials.
Class-Wide Cautions Worth Knowing
Some risks come from the wider drug class rather than from retatrutide findings. Phase 2 recorded one serious case of acute pancreatitis, with other pancreatic enzyme rises causing no symptoms.
Kidney strain is the other one. It ties back to dehydration from severe vomiting or diarrhea rather than any direct kidney effect.
Precautions before starting any of these medications include reviewing personal or family history of thyroid cancer, endocrine conditions, and pancreatitis.
How Many Patients Treated with Retatrutide Stopped?
Here is where the trials disagree most. In TRIUMPH-4, 18.2% of people on 12 mg stopped due to adverse effects. TRANSCEND-T2D-1 reported 5.1% at the same dose.
Lilly's triple agonist results from the pivotal TRIUMPH-1 trial landed between them. Discontinuation ran 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, against 4.9% on placebo.
The 4 mg number is the one worth sitting with. It came in below placebo, and that dose still produced 19% average weight loss over 80 weeks with just one escalation step.
Higher doses buy more weight loss. They also cost more in side effects, and the gap widens as you climb.
How Much Weight Did Participants Lose, and at What Cost?
Phase 2 participants at 12 mg saw average weight loss of 24.2% at 48 weeks, against 2.1% on placebo. TRIUMPH-1 delivered weight loss up to 25% at 80 weeks, reaching 30% in a subgroup escalated further.
TRIUMPH-4 studied people with obesity and knee osteoarthritis. Beyond significant weight loss, it showed substantial relief from osteoarthritis pain.
The tradeoff is the pattern in the table above. Higher doses drove more weight reduction and more frequent symptoms, which is the same balance you see across obesity treatment options.
How Do Retatrutide Side Effects Compare to Other Weight Loss Drugs?
Gastrointestinal rates land in similar territory at top doses. The differences show up elsewhere.
| Effect | Retatrutide 12 mg | Tirzepatide 15 mg | Semaglutide 2.4 mg |
|---|---|---|---|
| Nausea | 43% | About 29% | About 44% |
| Vomiting | 21% | About 10 to 12% | About 25% |
| Diarrhea | 33% | About 21% | About 30% |
| Heart rate rise | About 7 bpm | About 2 to 4 bpm | About 1 to 4 bpm |
| Dysesthesia | 20.9% | Not flagged | Flagged at higher dose |
One caution. These come from separate randomized controlled trials with different participants, not a head-to-head study.
No direct comparison trial has finished. Treat the gaps as rough rather than exact.
On retatrutide vs tirzepatide side effects, the clearest differences are the larger heart rate rise and the dysesthesia rate at 12 mg.
What Is the FDA Approval Status of Retatrutide?
Retatrutide is not yet approved by the FDA. It is moving through Phase 3 registrational trials, the last stage of testing before a company can file an application for review.
The pace has picked up. TRIUMPH-4 reported in December 2025, TRANSCEND-T2D-1 in March 2026, and the pivotal TRIUMPH-1 trial in May 2026, with all three meeting their main goals.
More results are due through the rest of 2026, including trials in type 2 diabetes and cardiovascular disease. Detailed TRIUMPH-1 findings are also headed to peer-reviewed publication.
Bottom Line
Retatrutide is an investigational drug in late-stage development by Eli Lilly. Because it is still being studied, there is no official side effect label yet. That list gets finalized if and when the FDA approves the medication.
Here is what the trials have shown so far:
- Gastrointestinal symptoms lead the list. Nausea, diarrhea, vomiting, and constipation were the most frequently reported, showing up mainly during dose increases and easing as the body adjusted.
- Side effects climb with dose. Rates at 12 mg ran well above 4 mg across every symptom, and so did the number of people who stopped treatment.
- Dysesthesia is the finding worth watching. This odd skin sensation appeared in 7% of Phase 2 participants and reached 20.9% at 12 mg in one Phase 3 trial, though most cases were mild and resolved during treatment.
- Serious events matched placebo. Both sat at 4% in Phase 2, with no medullary thyroid cancer and no C-cell hyperplasia reported.
- The full picture is still forming. More Phase 3 results land through 2026, and detailed findings are headed to peer-reviewed publication.
Dose size drove nearly every side effect rate in these trials. If you are working through dose math on any compound, our peptide calculator for injectable and oral equivalents covers retatrutide alongside BPC-157, GHK-Cu, and KPV, showing dose per injection, vial concentration, and the oral equivalent side by side.
This article is for educational purposes and is not medical advice. Retatrutide is an investigational compound still moving through clinical trials, with no approved supply available. Speak with a licensed healthcare provider before making decisions about any peptide or weight management treatment.
